EVALUATION OF GENETICALLY ENGINEERED CATTLE AND REFINING TECHNIQUES FOR PRODUCING THEM
Location: Animal Biosciences and Biotechnology Laboratory
Project Number: 1245-31000-091-00
Start Date: Jul 24, 2007
End Date: Jul 23, 2012
1. Develop a strategy for reducing drug resistance in S. aureus by identifying antimicrobial peptides that exhibit alternative modes of action. 1.A. Identify S. aureus surface structures that participate in resistance to peptidoglycan hydrolases and test triple acting fusion peptidoglycan hydrolases for their ability to evade the mechanisms identified. 1.B. Test candidate peptides in transgenic mice for their ability to protect against S. aureus infection. 2. Assess the merits of cloning and genetic enhancements in dairy cattle by evaluating clones and transgenic cattle and their offspring in a production setting with appropriate contemporaneous comparator animals. 2.A. Determine if a mammary gland specific transgene product can be detected in tissues other than the mammary gland throughout development of the transgenic cattle. 2.B. Determine if the cloning process substantially alters the epigenetic marking patterns between nuclear donor cells and their derived clones and the offspring of the clones. 2.C. Determine if clones, which are produced asexually, exhibit normal meiosis during the formation of their gametes.
Objective 1: PCR cloning will be utilized to fuse the mature form of lysostaphin to the phi11 endolysin and to the LysK endolysin. These fusion constructs will have CHAP endopeptidase, amidase and glycyl-glycyl endopeptidase domains. Imidazole step gradient on a nickel column will yield a phi11 endolysin-lysostaphin that is free of contaminating protein, to be used against S. aureus in a turbidity assay. A similar imidazole step gradient will be used to purify the LysK endolysin-lysostaphin construct. To determine if the endolysins (CHAP or amidase) contribute to cell lysis, each domain will be subjected to site-directed mutagenesis to inactivate domains one at a time. Objective 2. Tissues will be collected at slaughter from lactating transgenic females and pregnant females from each of the three lines, and from non-transgenic lactating females (negative control). Tissues will also be collected from at least one sexually mature bull from each of the lines. The tissues will be stored at -80C or 0.5 gm will be added to 2.5 ml of RNAlater, minced and then frozen until processed. The tissues to be collected include brain, blood, gonads, heart, kidney, muscle, liver, lung, lymph node, salivary gland, and spleen. All samples will be assayed for lysostaphin transgene mRNA expression (normalized to beta-actin expression), protein and biological activity as we have previously described. For gene-specific DNA methylation and histone acetylation, the bisulfite sequencing and Chromatin precipitation assay (CHIP) will be used. The methylation of cytosines in CpG dinucleotides will be determined from the sequence information of at least 10 independent clones. For the CHIP assay, antibodies specific to acetylated histones will be incubated with DNA in cells after fixation. Amplification of specific genes will be conducted by real-time PCR after bound DNA was precipitated by centrifugation. The amount of histone acetylation can be determined by the levels of amplification. Synaptonemal complex structure and chiasmata localization will be characterized by immunofluorescent staining of SCP3 (synaptonemal complex lateral element protein 3) and MLH1 (MutL homolog 1 mismatch repair protein) foci.